Funding
In July 2015 Ducentis raised seed finance from the founders and Oxford Technology, who specialise in funding Oxford-based technology companies with high growth prospects.
In 2015 and 2016 Ducentis successfully used this funding to demonstrate in vitro POC and file patents protecting high affinity variants of wild-type CD200 – thus securing ownership of novel molecules in what promises to be an important area of immune cell regulation.
Work in 2017 is focused on strengthening our current patent filing, completing in vitro and vivo POC efficacy studies, and preliminary safety and manufacturing studies.
In 2015 and 2016 Ducentis successfully used this funding to demonstrate in vitro POC and file patents protecting high affinity variants of wild-type CD200 – thus securing ownership of novel molecules in what promises to be an important area of immune cell regulation.
Work in 2017 is focused on strengthening our current patent filing, completing in vitro and vivo POC efficacy studies, and preliminary safety and manufacturing studies.
